Mechanisms of Disease Reversal in Focal and Segmental Glomerulosclerosis

Advances in Chronic Kidney Disease

Volumn 21, Issue 5, 2014, Pages 442-447

  Yang, Hai Chun ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Capillary; ECM; Glomerulosclerosis; Podocyte; Regression

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; DISEASE COURSE; DISEASE MODEL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLOMERULUS; HUMAN; METABOLISM; PATHOLOGY; PODOCYTE; REMISSION;

ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; PODOCYTES; REMISSION INDUCTION;

EID: 84906736347     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.04.001     Document Type: Review

References (55)

1. Fogo A.B. Progression and potential regression of glomerulosclerosis. Kidney Int 2001, 59(2):804-819.
2. Fioretto P., Steffes M.W., Sutherland D.E., Goetz F.C., Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998, 339:69-75.
3. Ruggenenti P., Perna A., Benini R., et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 1999, 10(5):997-1006.
4. Ma L.J., Nakamura S., Aldigier J.C., et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005, 16(4):966-976.
5. Aldigier J.C., Kanjanbuch T., Ma L.J., Brown N.J., Fogo A.B. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005, 16(11):3306-3314.
6. Davidson A.J. Uncharted waters: nephrogenesis and renal regeneration in fish and mammals. Pediatr Nephrol 2011, 26(9):1435-1443.
7. Leung K.C., Tonelli M., James M.T. Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol 2013, 9(2):77-85.
8. Remuzzi A., Gagliardini E., Sangalli F., et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006, 69(7):1124-1130.
9. Ikoma M., Kawamura T., Kakinuma Y., Fogo A., Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991, 40(2):195-202.
10. Fioretto P., Sutherland D.E., Najafian B., Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int 2006, 69(5):907-912.
11. Li L., Astor B.C., Lewis J., et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis 2012, 59(4):504-512.
12. Wilmer W.A., Hebert L.A., Lewis E.J., et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999, 34(2):308-314.
13. Ma L.-J., Fogo A.B. Role of angiotensin II in glomerular injury. Semin Nephrol 2001, 21:544-553.
14. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119(11):912-919.
15. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005, 14(3):235-241.
16. Ikoma M., Kawamura T., Fogo A., Ichikawa I. Cause of variable therapeutic efficiency of angiotensin-converting enzyme inhibitor on the glomerular mesangial lesions. Kidney Int 1991, 40:195-202.
17. Eddy A.A., Fogo A.B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006, 17(11):2999-3012.
18. Marinides G.N., Groggel G.C., Cohen A.H., Border W.A. Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. Kidney Int 1990, 37(2):749-757.
19. Tanaka R., Kon V., Yoshioka T., Ichikawa I., Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994, 45:537-543.
20. Ma L.-J., Nakamura S., Whitsitt J.S., Marcantoni C., Davidson J.M., Fogo A.B. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000, 58:2425-2436.
21. Adamczak M., Gross M.L., Krtil J., et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003, 14(11):2833-2842.
22. Remuzzi A., Gagliardini E., Donadoni C., et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002, 62(3):885-894.
23. Boffa J.J., Lu Y., Placier S., Stefanski A., Dussaule J.C., Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003, 14(5):1132-1144.
24. Zoja C., Corna D., Camozzi D., et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002, 13(12):2898-2908.
25. Ots M., Mackenzie H.S., Troy J.L., Rennke H.G., Brenner B.M. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc nephrol 1998, 9:224-230.
26. Fogo A.B. The potential for regression of renal scarring. Curr Opin Nephrol Hypertens 2003, 12(3):223-225.
27. Yusuf S., Teo K.K., Pogue J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15):1547-1559.
28. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367(23):2204-2213.
29. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369(20):1892-1903.
30. Gohlke P., Pees C., Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998, 31(1 Pt 2):349-355.
31. Andresen B.T., Romero G.G., Jackson E.K. AT2 receptors attenuate AT1 receptor-induced phospholipase D activation in vascular smooth muscle cells. J Pharmacol Exp Ther 2004, 309(1):425-431.
32. Vazquez E., Coronel I., Bautista R., et al. Angiotensin II-dependent induction of AT(2) receptor expression after renal ablation. Am J Physiol Ren Physiol 2005, 288(1):F207-F213.
33. Naito T., Ma L.J., Yang H., et al. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am J Physiol Ren Physiol 2010, 298(3):F683-F691.
34. Marcussen N., Nyengaard J., Christensen S. Compensatory growth of glomeruli is accomplished by an increased number of glomerular capillaries. Lab Invest 1994, 70:868-874.
35. Adamczak M., Gross M.L., Amann K., Ritz E. Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 2004, 15(12):3063-3072.
36. Scruggs B.S., Zuo Y., Donnert E., Ma L., Bertram J.F., Fogo A.B. Increased capillary branching contributes to angiotensin type 1 receptor blocker (ARB)-induced regression of sclerosis. Am J Pathol 2011, 178(4):1891-1898.
37. Liang X.B., Ma L.J., Naito T., et al. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol 2006, 17(7):1886-1895.
38. Combs H.L., Shankland S.J., Setzer S.V., Hudkins K.L., Alpers C.E. Expression of the cyclin kinase inhibitor, p27kip1, in developing and mature human kidney. Kidney Int 1998, 53(4):892-896.
39. Wharram B.L., Goyal M., Wiggins J.E., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005, 16(10):2941-2952.
40. Matsusaka T., Sandgren E., Shintani A., et al. Podocyte injury damages other podocytes. J Am Soc Nephrol 2011, 22(7):1275-1285.
41. Grahammer F., Wanner N., Huber T.B. Podocyte regeneration: who can become a podocyte?. Am J Pathol 2013, 183(2):333-335.
42. Ronconi E., Sagrinati C., Angelotti M.L., et al. Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol 2009, 20(2):322-332.
43. Ueno T., Kobayashi N., Nakayama M., et al. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int 2013, 83(6):1065-1075.
44. Fatima H., Moeller M.J., Smeets B., et al. Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin J Am Soc Nephrol 2012, 7(11):1852-1858.
45. Zhang J., Hansen K.M., Pippin J.W., et al. De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am J Physiol Ren Physiol 2012, 302(5):F571-F580.
46. Berger K., Schulte K., Boor P., et al. The regenerative potential of parietal epithelial cells in adult mice. J Am Soc Nephrol 2014, 25(4):693-705.
47. Shankland S.J., Anders H.J., Romagnani P. Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr Opin Nephrol Hypertens 2013, 22(3):302-309.
48. Pippin J.W., Sparks M.A., Glenn S.T., et al. Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease. Am J Pathol 2013, 183(2):542-557.
49. Macconi D., Sangalli F., Bonomelli M., et al. Podocyte repopulation contributes to regression of glomerular injury induced by ACE inhibition. Am J Pathol 2009, 174(3):797-807.
50. Zhang J., Pippin J.W., Vaughan M.R., et al. Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease. Nephron Exp Nephrol 2012, 121(1-2):e23-e37.
51. Zhang J., Pippin J.W., Krofft R.D., Naito S., Liu Z.H., Shankland S.J. Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Ren Physiol 2013, 304(11):F1375-F1389.
52. Wu J., Zheng C., Fan Y., et al. Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids. J Am Soc Nephrol 2014, 25(1):92-104.
53. Nemeth Z., Kokeny G., Godo M., et al. Increased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to monotherapies-the effect on podocytes. Nephrol Dial Transpl 2009, 24(12):3640-3651.
54. Kavvadas P., Weis L., Abed A.B., Feldman D.L., Dussaule J.C., Chatziantoniou C. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents. Hypertension 2013, 61(4):901-907.
55. Guerrot D., Dussaule J.C., Mael-Ainin M., et al. Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy. PloS One 2012, 7(3):e31974.